You are here: Industry Insights > tumour

News List

Cancer-fighting nano-robots programmed to seek and destroy tumours europeanpharmaceuticalreview
April 30, 2019
Study shows first applications of DNA origami for nanomedicine…
Delivering cancer treatment on a nanodisc helps eliminate tumours europeanpharmaceuticalreview
April 25, 2019
Novel platform for chemo-immunotherapy eliminated colon cancer in 85 percent of treated mice…
Bacterial therapy shows early promise in patients with advanced solid tumours europeanpharmaceuticalreview
April 19, 2019
Researchers have presented results of a Phase I clinical trial using bacterial Clostridium novyi-NT spores to target advanced solid tumours…
Researchers develop new prognostic test for colorectal cancer pharmatimes
March 08, 2019
High-risk stage two cancer patients could be identified more easily and accurately, due to a hopeful new prognostic method.
UK researchers devise new radiotherapy plan to reduce side effects pharmaceutical-technology
February 20, 2019
Physicists at The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust have devised a new treatment plan to avoid the impact of radiotherapy on sensitive organs near tumours and reduce associated side effects.....
UroGen appoints former Novartis cancer chief Barrett as CEO pharmaphorum
January 09, 2019
Novartis’ former oncology CEO Liz Barrett has left to join a little known biotech, UroGen, to help bring its potential urothelial cancer drug to market.
Seattle Genetics CEO lifts veil on lightning-quick Adcetris nod fiercepharma
December 05, 2018
SAN DIEGO—Seattle Genetics CEO Clay Siegall remembers reading about the first FDA approvals under the agency’s new Real Time Oncology Review pilot, secured 24 and 28 days after filing.
Purdue Pharma L.P. Announces Successful Completion of First-in-Human Study for Oncology Therapy Candidate Tinostamustine pharmafocusasia
December 03, 2018
Purdue Pharma L.P. today announced successful completion of a first-in-human Phase 1 dose escalation study of tinostamustine in patients with relapsed or refractory hematological malignancies for which there are no available therapies.
Pfizer doubles down in AML with Daurismo approval fiercepharma
November 28, 2018
Make that four drug approvals for Pfizer’s oncology unit in less than two months. In a welcome streak for the pharma giant—what with Lyrica generics looming—the FDA handed out a go-ahead for Daurismo, a treatment for acute myeloid leukemia.
Roche yanks Tecentriq kidney cancer apps in U.S., EU fiercepharma
November 22, 2018
Roche’s immuno-oncology rivals are hurtling toward a showdown in previously untreated kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.

Previous page 1 2 3 4 5 Next page